GlassScriptPhysician profile
Ryan Allen Burden
NPI 1932788239
$1,473.66
in general payments reported to CMS, 2019-2025
9 companies · $1,120 in 2025
The $1,120 reported for 2025 was more than what 95% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $16.12 · 2024: $337 · 2025: $1,120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,374 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,373.54 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $270.49 | 2024-2025 | Terlivaz |
| Janssen Biotech, INC. | $226.33 | 2025 | Tremfya |
| Laborie Medical Technologies Corp. | $179.74 | 2025 | |
| Abbvie INC. | $168.77 | 2025 | |
| Erbe USA INC | $150.00 | 2025 | Erbevio3apc3 |
| Genzyme Corporation | $130.12 | 2025 | |
| Celltrion USA INC. | $117.16 | 2024 | Zymfentra |
| Gilead Sciences, INC. | $116.82 | 2025 | Livdelzi |
| Takeda Pharmaceuticals U.S.A., INC. | $114.23 | 2022-2024 | Entyvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Burden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.